« Back
Home /
LY2562175

LY2562175

Item no.	HY-103704-25mg
Manufacturer	MedChem Express
CASRN	1103500-20-4
Amount	25 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Metabolism Cholesterol & Lipid Metabolism Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.49
Citations	[1]Genin MJ, et al. Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia. J Med Chem. 2015 Dec 24;58(24):9768-72.
Smiles	O=C(C1=CN(C)C2=C1C=CC(N3CCC(OCC4=C(C5CC5)ON=C4C6=C(Cl)C=CC=C6Cl)CC3)=C2)O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1103500-20-4
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Neuroscience-Neuromodulation
Manufacturer - Targets	Autophagy; FXR
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	540.44
Product Description	LY2562175 is a potent and selective FXR agonist, with an EC50 of 193 nM[1].
Manufacturer - Research Area	Metabolic Disease
Solubility	DMSO : 62.5 mg/mL (ultrasonic)
Manufacturer - Pathway	Autophagy; Metabolic Enzyme/Protease
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.